Onkologie. 2018:12(1):34-37 | DOI: 10.36290/xon.2018.008

Axitinib in the second-line treatment of metastatic renal cell carcinoma

Ondřej Fiala^1,2, Ondřej Šorejs¹, Tomáš Svoboda¹, Jindřich Fínek¹

¹ Onkologická a radioterapeutická klinika LF UK a FN Plzeň

² Biomedicínské centrum LF UK v Plzni

Background: Renal cell carcinoma (RCC) is the most common malignant tumour of the kidney in adults the incidence of whichhas been increasing significantly in the long term. Axitinib is a second-generation antiangiogenic multikinase inhibitor capable ofinhibiting the kinase activity of VEGFR 1, VEGFR 2, VEGFR 3, PDGFR, and c-KIT. The efficacy and safety of axitinib in the second-linetreatment of metastatic RCC have been confirmed in several clinical trials.

Case report: A 70-year-old man with multiple metastatic lesions of RCC was, following the failure of treatment with sunitinib inthe first line, treated with axitinib with a very good effect. Second-line treatment with axitinib resulted in partial regression andprogression-free survival with a duration of nearly 16 months. There was good treatment tolerance, without any significant toxicity.

Conclusion: Axitinib represents a modern agent for targeted therapy of metastatic RCC utilized in the second line, with a well-establishedefficacy and safety in both clinical trials and routine clinical practice.

Keywords: renal cell carcinoma, axitinib, second line, targeted therapy

Published: March 1, 2018  Show citation